Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANTRA: Angiotensin II vs Norepinephrine in Septic Shock
NCT06746753Phase 4Not yet recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of Angiotensin II in septic shock, sponsored by Wake Forest University Health Sciences. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Angiotensin II
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT06746753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746753.